Status:
COMPLETED
Evaluation of Different Doses of Letrozole in Ectopic Pregnancy
Lead Sponsor:
Zagazig University
Conditions:
Ectopic Pregnancy
Eligibility:
FEMALE
19-35 years
Phase:
PHASE4
Brief Summary
The utilization of letrozole at a daily dose of 10 mg for medical treatment of ectopic pregnancy considerably has a high success rate without imposing any serious side effects compared to daily 5mg le...
Detailed Description
Letrozole, an aromatase inhibitor, has recently been introduced as favorable medical treatment for ectopic pregnancy. We aimed at evaluating the effects of different doses of letrozole for induction o...
Eligibility Criteria
Inclusion
- Diagnosed ectopic pregnancy was by
- Absence of an intrauterine gestational sac on vaginal ultrasound Coupled with
- β-hCG titers beyond the discrimination zone of at least 2,000 milli-International units (mIU/m).
Exclusion
- Patients had contraindications for letrozole
- Patients with any systemic disease ( diabetes, hypertension, ....)
- Patients with b-hCG levels \>3,000 mIU/mL
- Patients with hemoglobin level \<10 g/dL,
- Patients with platelets count \<150,000/mL,
- Patients with elevated liver enzymes,
- Patients with elevated blood urea, or serum creatinine
- The presence of a fetal heartbeat in a gestational sac detected outside the uterine cavity
Key Trial Info
Start Date :
December 15 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05198141
Start Date
December 15 2020
End Date
January 1 2022
Last Update
January 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohamed ALI Alabiad
Zagazig, Sharqia Province, Egypt, 14150